Fennec Pharmaceuticals
FENC
Fennec Pharmaceuticals (FENC) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.05
- EPS estimate
- $0.02
- EPS surprise
- +150.00%
- Revenue surprise
- +10.29%
- Revenue
- $17.9M
- Revenue estimate
- $16.2M
- Reported
- Aug 13, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 13, 2026 | $0.02 | $0.05 | +150.00% | $17.9M | SEC |
| Q1 2026 | May 14, 2026 | −$0.04 | $0.01 | +122.78% | $15.1M | SEC |
| Q4 2025 | Mar 24, 2026 | $0.04 | −$0.17 | −504.76% | $13.8M | SEC |
| Q3 2025 | Nov 13, 2025 | −$0.02 | −$0.02 | +9.05% | $12.6M | SEC |
| Q2 2025 | Aug 14, 2025 | −$0.03 | −$0.11 | −219.20% | $9.8M | SEC |
| Q1 2025 | May 14, 2025 | −$0.09 | −$0.04 | +55.90% | $8.5M | SEC |
| Q4 2024 | Mar 10, 2025 | −$0.13 | −$0.06 | +53.19% | $7.9M | SEC |
| Q3 2024 | Nov 8, 2024 | −$0.09 | −$0.22 | −136.48% | $7.1M | SEC |
| Q2 2024 | Aug 13, 2024 | −$0.02 | −$0.20 | −718.78% | $7.3M | SEC |
| Q1 2024 | May 14, 2024 | −$0.06 | $0.41 | +818.26% | $25.6M | SEC |
| Q4 2023 | Mar 25, 2024 | −$0.02 | −$0.10 | −454.89% | $9.9M | SEC |
| Q3 2023 | Nov 7, 2023 | −$0.12 | −$0.07 | +40.61% | $6.5M | SEC |
| Q2 2023 | Aug 4, 2023 | −$0.16 | −$0.21 | −33.80% | $3.4M | SEC |
| Q1 2023 | May 12, 2023 | −$0.20 | −$0.23 | −13.41% | $1.7M | SEC |
| Q3 2022 | Nov 14, 2022 | −$0.18 | −$0.30 | −67.06% | $0.00 | — |
| Q2 2022 | Aug 12, 2022 | −$0.14 | −$0.19 | −39.64% | $0.00 | — |
| Q1 2022 | May 12, 2022 | −$0.14 | −$0.15 | −1.46% | $0.00 | — |
| Q4 2021 | Feb 28, 2022 | $0.76 | −$0.18 | −123.88% | $0.00 | — |
| Q3 2021 | Nov 10, 2021 | −$0.17 | −$0.16 | +6.50% | $0.00 | — |
| Q2 2021 | Aug 10, 2021 | −$0.19 | −$0.15 | +18.66% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Fennec Pharmaceuticals (FENC) last report earnings?
Fennec Pharmaceuticals last reported on Aug 13, 2026, covering fiscal Q2 2026.
Did FENC beat earnings estimates?
Yes. Fennec Pharmaceuticals reported EPS of $0.05 for Q2 2026 against a $0.02 estimate — a 150.00% beat.
How much revenue did FENC report last quarter?
Fennec Pharmaceuticals reported $17.9M in revenue for Q2 2026, against a consensus estimate of $16.2M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.